Floatz logo

Tinzaparin

Pancreas Neoplasm

Helsinki University Central Hospitalother_biologicalPhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

381 Active assets in the Pancreas Neoplasm cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Irinotecan
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Tinzaparin is also rated in:

BleedingDormant
BB
Indicative ·
65 / 100
View asset →
thrombotic diseaseDormant
BB
Indicative ·
65 / 100
View asset →
venous thromboembolismDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →